Nephrogenic Systemic Fibrosis

Overview

Nephrogenic systemic fibrosis (NSF) is a rare condition in which the skin and the connective tissues beneath it become thickened, hardened, and tight. The word "nephrogenic" reflects that it occurs almost exclusively in people with severe kidney disease, including those on dialysis.

NSF was linked to the use of certain gadolinium-based contrast dyes given during MRI scans in people with poor kidney function. After this connection was recognized and guidelines changed, new cases became very uncommon. The condition can affect not only the skin but also joints and, in some people, internal organs.

Symptoms

Symptoms usually begin in the limbs and develop over days to weeks:

• Thickening and hardening of the skin, often on the legs, arms, and trunk
• Skin that looks shiny, darkened, or has a woody, "orange-peel" texture
• Tightness that limits movement of joints and can cause contractures
• Burning, itching, or pain in the affected areas
• Reduced mobility, sometimes severe, if joints become fixed

In some people, fibrosis extends to deeper tissues and organs such as muscle, the heart, or the lungs, which can affect overall health.

Causes

The central factor is severe kidney impairment, which is present in essentially all cases. In people whose kidneys cannot clear it well, exposure to certain older gadolinium-based contrast agents used for MRI scans was identified as the main trigger.

When kidney function is very poor, gadolinium is cleared from the body slowly, and in susceptible people this appears to set off a process of abnormal tissue scarring. Not everyone exposed developed NSF, so other contributing factors are thought to play a role. Since safer practices were adopted, the condition has become rare.

Risk Factors

• Severe or end-stage kidney disease, including those on dialysis
• Acute kidney injury at the time of contrast exposure
• Exposure to higher-risk gadolinium-based MRI contrast agents in the setting of poor kidney function
• Possibly repeated or high-dose contrast exposure

Diagnosis

Diagnosis is based on the clinical picture in someone with kidney disease, supported by:

• Medical history: Including kidney function and any past MRI contrast exposure.
• Skin biopsy: A deep biopsy showing the characteristic pattern of thickening and fibrosis helps confirm the diagnosis.
• Exclusion of similar conditions: Such as scleroderma and other fibrosing disorders.

Treatment

There is no single, reliably effective cure for NSF, so care focuses on the kidneys, symptoms, and function.

• Improving kidney function: Restoring kidney function, where possible, including through kidney transplantation, offers the best chance of improvement.
• Physical therapy: Stretching and exercise are important to maintain joint movement and limit contractures.
• Symptom relief: Treatments are used to ease pain, itching, and skin tightness.
• Other therapies: Various medical and physical treatments have been tried with variable results.

Outcomes vary; some people stabilize or improve, particularly if kidney function recovers, while others have persistent skin and joint changes.

Prevention

Prevention has been the most successful approach and is the reason cases are now rare:

• Avoiding or limiting higher-risk gadolinium contrast agents in people with severe kidney disease
• Checking kidney function before contrast-enhanced MRI when kidney disease is a concern
• Using the lowest necessary dose of safer contrast agents only when truly needed
• Considering dialysis timing after contrast for some patients, as advised by the care team

When to See a Doctor

If you have kidney disease and notice new thickening, hardening, tightness, darkening, or itching of the skin, especially on the limbs, contact your doctor. Early evaluation helps confirm the cause and start physical therapy to protect joint movement.

If you have severe kidney disease and need an MRI with contrast, tell the care team about your kidney function so they can choose the safest approach.

Related Topics

Frequently Asked Questions

References

1. MedlinePlus, U.S. National Library of Medicine. Nephrogenic systemic fibrosis.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
3. U.S. Food and Drug Administration (FDA). Gadolinium-based contrast agents.
4. National Organization for Rare Disorders (NORD). Nephrogenic Systemic Fibrosis.